All Cancer Clinical Trials

Treatment

A Multi-Center Open-Label Phase I/2 Study of BGB324 in Combination with Erlotinib in Patients with Stage IIIb or Stage IV Non-Small Cell Lung Cancer

A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab- Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Advanced or Metastatic Cholangiocarcinoma

A Multi-arm Phase I Safety Study of Nivolumab in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)

A Multicenter Phase 1/2b Study of the Bruton[Single Quote]s Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination with Carfilzomib (Kyprolis(TM)) in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma

A Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma

A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

A Multicenter Randomized Phase II Study of NPC-1C in Combination with Gemcitabine and nab-Paclitaxel versus Gemcitabine and nab-Paclitaxel alone in Patients with Metastatic or Locally Advanced Pancreatic Cancer Previously Treated with FOLFIRINOX

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer

A Multicenter, Randomized, Open-label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients With Advanced Multiple Myeloma

A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF QUIZARTINIB (AC220) MONOTHERAPY VERSUS SALVAGE CHEMOTHERAPY IN SUBJECTS WITH FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA (AML) REFRACTORY TO OR RELAPSED AFTER FIRST-LINE TREATMENT WITH OR WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) CONSOLIDATION

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO COMPARE EFFICACY AND SAFETY OF ORAL AZACITIDINE PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE AS MAINTENANCE THERAPY IN SUBJECTS WITH ACUTE MYLOID LEUKEMIA IN COMPLETE REMISSION

A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO[?] CONTROLLED, MULTICENTER STUDY OF VS-6063 IN SUBJECTS WITH MALIGNANT PLEURAL MESOTHELIOMA

A Phase 1 Study of Substance P-Saporin with Histologically Confirmed Advanced Cancer Patients with Chronic Pain

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma

A Phase 1 Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation

A Phase 1-2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT

A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody in Adults with Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer after Standard Therapy

A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study of AG-221 in Subjects with Advanced Solid Tumors, including Glioma, and with Angioimmunoblastic T-cell Lymphoma, that Harbor an IDH2 Mutation

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

A Phase 1B Clinical Trial of Trametinib plus Digoxin in Patients with Unresectable or Metastatic BRAF wild-type Melanoma

A Phase 1B Dose Escalation Study to Investigate the Safety, Tolerability and Preliminary Efficacy for the Combination of Dasatinib (BMS-354825) plus Nivolumab (BMS-936558) in Patients with Chronic Myeloid Leukemia (CML)

A Phase 1B Open-Label, Dose-Escalation Study Of The Safety, Tolerability, And Pharmacokinetics Of MEHD7945a And Cobimetinib In Patients With Locally Advanced Or Metastatic Cancers With Mutant KRAS

A Phase 1b Multicenter, Open-Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Safety, And Antitumor Activity Of An Alternative Liquid Formulation Of Acy-1215 (Ricolinostat) In Combination With Pomalidomide And Low-Dose Dexamethasone In Patients With Relapsed or Relapsed-And-Refractory Multiple Myeloma

A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma

A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer

A Phase 3, Multicenter, Open-Label, Randomized Study of nab(RegisteredTM)-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)

A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

A Phase I CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy Study for Early-stage Glottic Larynx Cancer

A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects with Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA

A Phase I Study of Cyberknife(RegisteredTM) Partial Breast Irradiation (PBI) for Early Stage Breast Cancer

A Phase I Study of Reduced-Volume Hypofractionated, PET-directed Intensity Modulated Radiotherapy Concurrent with Weekly Cisplatin Chemotherapy for T1/2N0-2 Squamous Cell Carcinoma of the Head and Neck

A Phase I Study of the Phosphatidylserine-Targeting Antibody Bavituximab in Combination with Capecitabine and Radiation Therapy for the Treatment of Stage II and III Rectal Adenocarcinoma

A Phase I Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer

A Phase I dose escalation study of ARQ 761 (Beta-Lapachone) in adult patients with advanced solid tumors

A Phase I open-label study of the safety and pharmacokinetics of escalating doses of DNIB0600A in patients with non-small cell lung cancer and platinum-resistant ovarian cancer

A Phase IB Study of A-dmDT390-bisFv (UCHT1) Fusion Protein in Patients with Surface CD3+ Malignant T Cell Diseases

A Phase II Study for Image Guided Hypofractionated Radiation Boost Therapy for Definitive Treatment of Locally Advanced Cervical Cancer

A Phase II Study of Pioglitazone for patients with cancer of the pancreas

A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors

A Phase II Trial of High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy (SABR) for Patients with Metastatic Clear Cell Renal Cell Cancer (mRCC)

A Phase II Trial of Stereotactic Ablative Body Radiation Therapy (SABR) for patients with primary Renal Cancer (RCC)

A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute(RegisteredTM)- Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

A Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer

A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma

A Pilot Study of * OncozeneTM * Microspheres for intra-arterial delivery of doxorubicin for the treatment of patients with unresectable hepatocellular cancer

A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM

A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLOWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)

A RANDOMIZED, PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMA

A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age.

A Randomized Phase III Trial of the value of early local therapy for the intact primary tumor in patients with metastatic breast cancer

A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer

A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects with Waldenstr[?]m[Single Quote]s Macroglobulinemia

A Randomized, Open-Label Study Comparing the Combination of YONDELIS(RegisteredTM) and DOXIL(RegisteredTM)/CAELYX(RegisteredTM) With DOXIL(RegisteredTM)/CAELYX(RegisteredTM) Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

A Randomized, Placebo-Controlled, Double-Blind,Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)

A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)

A Safety and Tolerability Trial of Crenolanib and Chemotherapy with Cytarabine and Anthracyclines in Patients with Newly Diagnosed Acute Myeloid Leukemia with FLT3 Activating Mutations

A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)

A Two-Arm, Single Center Phase IB Trial of Bavituximab plus Ipilimumab in Advanced Melanoma Patients

A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib(GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection

A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment-(BKM 120-2303)

A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study

A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3N1) Who Have Positive sentinel Lymph Node Disease after Neoadjuvant Chemotherapy

A031201: PHASE III TRIAL OF ENZALUTAMIDE (NSC # 766085) VERSUS ENZALUTAMIDE, ABIRATERONE AND PREDNISONE FOR CASTRATION RESISTANT METASTATIC PROSTATE CANCER

A041202: A RANDOMIZED PHASE III STUDY OF BENDAMUSTINE PLUS RITUXIMAB VERSUS IBRUTINIB PLUS RITUXIMAB VERSUS IBRUTINIB ALONE IN UNTREATED OLDER PATIENTS (>= 65 YEARS OF AGE) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

A081105:RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ERLOTINIB OR PLACEBO IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)

A091201: RANDOMIZED PHASE II STUDY COMPARING THE MET INHIBITOR CABOZANTINIB TO TEMOZOLOMIDE/DACARBAZINE IN OCULAR MELANOMA

AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)

AALL1122, A Phase 2 Multi-Center Historically - Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum

AALL1231, A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

AALL1421 (13-011), A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Pegaspargase (Oncaspar(RegisteredTM))

AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD

AAML1321 (CAMN1072203), A Multi-Center, Open Label, Non-Controlled Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients with Newly Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) or with Ph+ CML in CP or Accelerated Phase (AP) Resistant or Intolerant to either Imatinib or Dasatinib

ACCL0922, (SCUSF 0901) A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor

ACCL0933, A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

ACCL1131, A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)

ACNS0331: A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial

ACNS0332, Efficacy of Carboplatin administered Concomitantly with Radiation and Isotretinoin as a Prop-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients.

ACNS0821, Temozolomide with Irinotecan Versus Temozolomide, Irinotecan plus Bevacizumab for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

ACNS1022, A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

ACNS1123, Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors

ACOSOG Z11102 Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)

ADVL0912, A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-MET, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma

ADVL1322 (GSK VEG116731), A Phase II Study of Pazopanib GW786034, NSC# 737754 in Children, Adolescents and Young Adults with Refractory Solid Tumors

AEWS1031, A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma

AEWS1221, Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

AHEP0731, Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment

ANBL0032: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch 14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

ANBL09P1, A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma

ANBL1221,A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma

ANBL1232, Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

ANBL12P1,Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma

ANHL1131, Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma (NHL) or Mature B-cell Leukemia (B-AL): Evaluation of Rituximab Efficacy and Safety in High Risk Patients

ANHL12P1, A Randomized Phase II study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND #117117

AOST1322, Phase II Study of Eribulin (IND# 122686, NSC# 707389) in Recurrent or Refractory Osteosarcoma

AREN0534, Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor

ARET0321, A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma

ARQ197-A-U303 A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF TIVANTINIB (ARQ 197)IN SUBJECTS WITH MET DIAGNOSTIC-HIGH INOPERABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH ONE PRIOR SYSTEMIC THERAPY

ARST1321, Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)

ASCT1221, A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children with Juvenile Myelomonocytic Leukemia (JMML)

BP-U-004, Phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR (RegisteredTM)[BETA]+T cells in pediatric patients affected by hematological disorders

BTTC09-01: A Phase I-II trial Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas

BTTC12-01: A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab

CALGB 30610/RTOG 0538: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

CALGB C80702- A PHASE III TRIAL OF 6 VERSUS 12 TREATMENTS OF ADJUVANT FOLFOX PLUS CELECOXIB OR PLACEBO FOR PATIENTS WITH RESECTED STAGE III COLON CANCER

CFZ008, Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia

CRAD001CUS224T, Phase II Study of Everolimus (RAD001, AFINITOR(RegisteredTM)) for Children with Recurrent or Progressive Ependymoma

Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study

E1411: Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB [?] R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV[?] R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB [?] LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV [?] LR)

E1412: Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

E1912: A Randomized Phase III Study of Ibrutinib (PCI- 32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

E2112:A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer

E2211:A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors

E2511: Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer

E2607: A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas

E3A06: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asympotomatic High-Risk Smoldering Multiple Myeloma

E3F05 Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas

E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

EP-ILC-201, Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma

GOG 0244: The Lymphedema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors and Impact in Newly Diagnosed Patients

GOG 0275: A PHASE III RANDOMIZED TRIAL OF PULSE ACTINOMYCIN-D VERSUS MULTI-DAY METHOTREXATE FOR THE TREATMENT OF LOW-RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA

GOG 0277- (IRCI 001): A Phase III Randomized Trial of Gemcitabine (NSC# 613327) plus Docetaxel (NSC# 628503) followed by Doxorubicin (NSC# 123127) v. observation for uterus-limited, High Grade Uterine Leiomyosarcoma

GOG 0279: A PHASE II TRIAL EVALUATING CISPLATIN (NSC #119875) AND GEMCITABINE (NSC #613327) CONCURRENT WITH INTENSITY-MODULATED RADIATION THERAPY (IMRT) IN THE TREATMENT OF LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE VULVA

GOG 0286B: A RANDOMIZED PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN/METFORMIN (NSC#91485) VERSUS PACLITAXEL/CARBOPLATIN/PLACEBO AS INITIAL THERAPY FOR MEASURABLE STAGE III OR IVA, STAGE IVB, OR RECURRENT ENDOMETRIAL CANCER NCT #022065687

GOG 0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-stage Cervical Carcinoma Following Radical Hysterectomy

GOG 238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus

GOG 263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy

GOG 264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary

GOG 265: A Phase II Evaluation of ADXS11-001 (NSC 752718, BB-IND #13,712) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix

GOG 274: A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)

GOG 281:A RANDOMIZED PHASE II/III STUDY TO ASSESS THE EFFICACY OF TRAMETINIB (GSK 1120212) IN PATIENTS WITH RECURRENT OR PROGRESSIVE LOW-GRADE SEROUS OVARIAN CANCER OR PERITONEAL CANCER.

GOG-0076HH: A Phase I/II Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (IND#77840, NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix

GOG-0225: CAN DIET AND PHYSICAL ACTIVITY MODULATE OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER PROGRESSION-FREE SURVIVAL

GOG-0283: A PHASE II TRIAL OF DCTD-SPONSORED DASATINIB (NSC #732517 IND #120636) IN RECURRENT /PERSISTENT OVARY, FALLOPIAN TUBE, PRIMARY PERITONEAL, AND ENDOMETRIAL CLEAR CELL CARCINOMA CHARACTERIZED FOR THE RETENTION OR LOSS OF BAF250a EXPRESSION

I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2)

M9177: Phase II Study of Dose-Adjusted EPOCH+/- Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma

Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial

N1174: Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naive Patients with Recurrent Glioblastoma Multiforme

NMTRC 003B, A Phase II Preventative Trial of DFMO (eflornithine HCl) as a Single Agent in Patients with High Risk Neuroblastoma in Remission

NMTRC V0706, A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma

NRG BN001 Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma

NRG-HN001: RANDOMIZED PHASE II AND PHASE III STUDIES OF INDIVIDUALIZED TREATMENT FOR NASOPHARYNGEAL CARCINOMA BASED ON BIOMARKER EPSTEIN BARR VIRUS (EBV) DEOXYRIBONUCLEIC ACID (DNA)

NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

PPHM 1202: SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone in Patients with Previously Treated Stage IIIb/IV Non-Squamous Non-Small-Cell Lung Cancer

Phase 1B study of PD-0332991 in combination with T-DM1 in the treatment of patients with advanced HER2-positive breast cancer

Phase 2 open label trial of oral intermittent dacomitinib in patients with advanced NSCLC

Phase 3, Randomized, Placebo-Controlled, Double-blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) in Combination with Erlotinib in EGFR Wild-type Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy

Phase I/II Trial of Fenretinide/LXS oral powder (NSC 374551) plus Ketoconazole in Recurrent Ovarian Cancer, Fallopian Tubes and Primary Peritoneal Carcinoma

Phase II Study of Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer with Injectable Rectal Spacer

Phase II Trial of Hippocampal-Avoiding Whole Brain Irradiation with Simultaneous Integrated Boost for Treatment of Brain Metastases

Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Patients with metastatic castrate-resistant Prostate Cancer (mCRPC)

Phase II multicenter randomized, double blind, placebo controlled study assessing the efficacy of buparlisib (BKM120) plus paclitaxel vs. placebo plus paclitaxel in patients with platinum pre-treated recurrent or metastatic head and neck squamous cell carcinoma

Phase II study of VS-6063, a Focal Adhesion Kinase (FAK) inhibitor, in patients with KRAS mutant non-small cell lung cancer

Phase II study of enzalutamide (MDV3100) and gonadotropin-releasing hormone (GnRH) agonist before, during and after radiation therapy in treatment of patients with high-risk localized prostate cancer

Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, with correlative studies in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.

Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma

Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status

Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The Catnon Intergroup Trial

PrECOG 0102-Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant (Faslodex) plus Everolimus in Post-Menopausal Patients with Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy

Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CSF3R

RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT-NA[?]VE ANAPLASTIC LYMPHOMA KINASE[?]POSITIVE ADVANCED NON[?]SMALL CELL LUNG CANCER

RTOG 0813: Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients

RTOG 0912: A RANDOMIZED PHASE II STUDY OF CONCURRENT INTENSITY MODULATED RADIATION THERAPY (IMRT), PACLITAXEL AND PAZOPANIB (NSC 737754)/PLACEBO, FOR THE TREATMENT OF ANAPLASTIC THYROID CANCER

RTOG 1008 A RANDOMIZED PHASE II STUDY OF ADJUVANT CONCURRENT RADIATION AND CHEMOTHERAPY VERSUS RADIATION ALONE IN RESECTED HIGH-RISK MALIGNANT SALIVARY GLAND TUMORS

RTOG 1122 PHASE II DOUBLE-BLINDED PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA

RTOG 1203 A RANDOMIZED PHASE III STUDY OF STANDARD VS. IMRT PELVIC RADIATION FOR POST-OPERATIVE TREATMENT OF ENDOMETRIAL AND CERVICAL CANCER (TIME-C)

RTOG 1216 RANDOMIZED PHASE II/III TRIAL OF SURGERY AND POSTOPERATIVE RADIATION DELIVERED WITH CONCURRENT CISPLATIN VERSUS DOCETAXEL VERSUS DOCETAXEL AND CETUXIMAB FOR HIGH-RISK SQUAMOUS CELL CANCER OF THE HEAD AND NECK

RTOG 1306 A RANDOMIZED PHASE II STUDY OF INDIVIDUALIZED COMBINED MODALITY THERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)

RTOG 631 Phase II/III study of image-guided radiosurgery/SBRT for localized spine metastasis

RTOG 815 PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER

RTOG 839 RANDOMIZED PHASE II STUDY OF PRE-OPERATIVE CHEMORADIOTHERAPY +/- PANITUMUMAB (IND #110152) FOLLOWED BY CONSOLIDATION CHEMOTHERAPY IN POTENTIALLY OPERABLE LOCALLY ADVANCED (STAGE IIIA, N2+) NON-SMALL CELL LUNG CANCER

RTOG 920 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

RTOG 924 ANDROGEN DEPRIVATION THERAPY AND HIGH DOSE RADIOTHERAPY WITH OR WITHOUT WHOLE-PELVIC RADIOTHERAPY IN UNFAVORABLE INTERMEDIATE OR FAVORABLE HIGH RISK PROSTATE CANCER: A PHASE III RANDOMIZED TRIAL

Randomized Trial of Adjuvant Curcumin after Radical Prostatectomy

Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer

Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Randomized, Double-Blind, Vehicle-Controlled Pilot Study of the Efficacy and Safety of HylaCareTM in the Treatment of Acute Skin Changes in Patients Undergoing External Beam Radiotherapy for Tumors of the Breast.

Risk-Adapted Therapy for Young Children with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma or Ependymoma (SJYC07)

S1007: Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/-Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

SBRT Spine: Phase II Study of Stereotactic Body Radiation Therapy and Vertebroplasty for Localized Spinal Metastasis

SJMB12, A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

SPOC-2012-001, Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

SPOC-2013-001, Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb(LXS) Oral Powder Plus Ketoconazole Plus Vincristine in Patients with Recurrent or Resistant Neuroblastoma (IND #: 68,254)

SPOC-2014-001, Expanded Access Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb(LXS) Oral Powder Plus Ketoconazole in Patients with Recurrent or Resistant Neuroblastoma (IND #68,254)

Success of active surveillance in patients with untreated small renal masses with the option of delayed treatment.

T2009-003, A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL

T2009-012, A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies

TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

TOPNOC 001 (H-24549), A Phase II Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children with Newly Diagnosed High-Grade Gliomas or Brainstem Gliomas

The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing the efficacy of MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma

`A Phase 1, Multiple-dose, dose-escalation Trial of PT2385 Tablets, A Hif-2(RegisteredTM) Inhibitor, in Patients with Advanced Clear Cell Renal Cell Carcinoma

Supportive Care

ACCL10P1, Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study

GOG 0278: EVALUATION OF PHYSICAL FUNCTION AND QUALITY OF LIFE (QOL) BEFORE AND AFTER NON-RADICAL SURGICAL THERAPY (EXTRA FASCIAL HYSTERECTOMY OR CONE BIOPSY WITH PELVIC LYMPHADENECTOMY) FOR STAGE IA1 (LVSI+) and IA2-IB1 (<= 2CM) CERVICAL CANCER

Diagnostic

A Clinical, non-intervention study of the Cxbladder(RegisteredTM) urine test for the detection of recurrent urinary tract Urothelial Carcinoma (UC)

Advanced MR Imaging Techniques in the Characterization of Renal Cell Carcinoma: Correlation with Pathology and Gene Expression Profiles

Clinical Development of MR Spectroscopy and Imaging in Brain Cancers

Deciphering androgen receptor signaling in primary prostate tissue

Evaluation of the UroVysion Test in Predicting Recurrence and/or Progression of Disease in Patients Receiving initial BCG for Primary High Grade Papillary Ta-T1 and CIS Urothelial Carcinoma of the Bladder

Feasibility Study using Imaging Biomarkers in Lung Cancer

High Resolution Magnetic Resonance Imaging in Patients with Brain Tumors

Investigating the Feasibility of Using Rapid Cine-MRI for Monitoring Moving and Deforming Tumors

Investigation of Diagnostic Improvement Gained through Optimization of MR Methods for Breast Cancer Detection

Pilot study to investigate potential clinical applications of newly identified general tumor markers

Quantitative Magnetic Resonance Imaging (qMRI) for the Physiological Characterization of Tumors in the Lung

Technology Development for Intracellular Metabolites at 7 Tesla

Transfusional Iron Overload in Children Treated for Cancer

Screening

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

ALTE11C2, Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy

Aurora Kinase A as a Biomarker for the Detection of Bladder Cancer

Feasibility of CT Perfusion (CTP) as a noninvasive method for characterizing pulmonary lesions as benign or malignant: Comparison of CTP findings with histopathology and other imaging results.

RCT of strategies to improve screening rates among a cohort of cirrhotic patients at high risk for developing HCC, in a safety-net health system.

UT Southwestern Hepatocellular Carcinoma (HCC) Early Detection Study

Use of the CA-125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

Prevention

ALTE11C1, Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma

Adjunctive Smart Phone Based Smoking Cessation Treatment

BTTC11-01: Randomized, double-blind, placebo-controlled trial of lacosamide for seizure prophylaxis in patients with High-Grade Gliomas

CMX001-301: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients

Developing a self-persuasion intervention promoting adolescent HPV vaccination

GOG-270: GROningen INternational Study on Sentinel nodes in Vulvar cancer(GROINSS-V) II: An Observational Study

T2008-002, A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL, POETIC and ITCC